



Universiteit
Leiden
The Netherlands

Immune-based therapies in ovarian cancer

Dijkgraaf, E.M.

Citation

Dijkgraaf, E. M. (2017, June 13). *Immune-based therapies in ovarian cancer*. Retrieved from <https://hdl.handle.net/1887/49549>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/49549>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/49549> holds various files of this Leiden University dissertation.

Author: Dijkgraaf, E.M.

Title: Immune-based therapies in ovarian cancer

Issue Date: 2017-06-13

IMMUNE-BASED THERAPIES IN OVARIAN CANCER

1. IL-6 and IL-6R are opposite markers for myeloid cell infiltration and survival. *this thesis*
2. Gemcitabine treatment decreases myeloid derived suppressor cells in humans. *this thesis*
3. IL-6R blocking, in combination with chemotherapy, has an acceptable safety profile and a possible immunological benefit in patients with recurrent ovarian cancer. *this thesis*
4. Gemcitabine treatment, immune modulation with Pegintron and therapeutic vaccination is a well-tolerated approach in the development of combined chemo-immunotherapeutic regimens to treat cancer. *this thesis*
5. The success of combining different forms of immunotherapy and chemotherapy depends on our ability to optimize the dose and schedule of the combination regimen and to manage its toxicity. *this thesis*
6. Chemotherapies and immunotherapies must be combined effectively to attack the tumor from multiple sides to quickly and thoroughly eliminate cancer (*GM Weir, Cancers 2011 Aug 5;3(3):3114-42*) necessitating a thorough understanding of the impact of each chemotherapeutic compound on the immune system.
7. While the field of cancer immunotherapy has had a great number of FDA approval for immunotherapy, the next crucial step in chasing the costs are future breakthroughs in validated biomarker development.
8. Both PITCH and CHIP are subtle shots to reach the final target.
9. In life as in career, it are our choices that show what we truly are, far more than our abilities. *Albus Dumbledore, Harry Potter and the Chamber of Secrets (1998)*
10. He who has never changed his opinion has rarely learned anything. *loosely translated from slogan NRC Handelsblad*